← All trials
NCT05374057
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 23, 2022
- Primary completion
- May 31, 2023
- Completion date
- Aug 31, 2024
- First posted
- May 13, 2022
- Last posted
- May 24, 2022
- Enrollment
- 320
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Oslo Metropolitan UniversityLead sponsor
- University Hospital, AkershusStudy director
- University of OsloCollaborator
- University of OsloOverall official - principal investigator
- Oslo Metropolitan UniversityReponsible party - principal investigator
- The Dam FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.